Recent studies indicated that hRNase 5 serves as a ligand for the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) and plexin-B2 (PLXNB2) receptor13–15 in solid and hematopoietic cancers. This evidence concerns the gene EGFR and hematopoietic and lymphoid cell neoplasm.